Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

BioTime, Inc. (BTX): Neal C. Bradsher Keeps Buying More Shares

As a new filing with the Securities and Exchange revealed, Neal C. Bradsher‘s Broadwood Capital has acquired a significant position in BioTime, Inc. (NYSEMKT:BTX) and raised its stake to nearly 17.90 million shares of the company. Broadwood acquired approximately 4.04 million shares in one transaction at a price of $3.12 per unit. The new stake amasses around 22% of the company and is activist by nature, with Mr. Bradsher serving on Biotime’s board of directors.


Broadwood Capital has been a shareholder of BioTime, Inc. (NYSEMKT:BTX) for nearly 10 years, the fund first initiating a substantial stake in the company in January 2004, as the records in filings with the Securities and Exchange Commission show.  The stock gained over 200% since then and Mr. Bradsher raised his fund’s exposure from some 1.12 million shares the fund disclosed in its first 13D filing regarding BioTime, Inc. (NYSEMKT:BTX). Mr. Bradsher has been serving on the company’s board since 2009 with the stock of the company going through significant boost for the next several years, reaching as high as over $9.4 per share. Aside from Broadwood Capital, among the investors that we track at Insider Monkey, other shareholders of the company own small positions in Biotime. David E. Shaw‘s D E Shaw owns around 50,500 shares of the company and Israel Englander‘s Millennium Management hold 17,400 shares, both as of the end of June.

Despite amassing a significant position in BioTime, Inc. (NYSEMKT:BTX) over the years, the company is still not the largest holding in Broadwood’s equity portfolio. Broadwood has a very concentrated portfolio with only six positions, and the stake in BioTime is the sixth-largest in terms of value, representing around 7.5% of the portfolio. Broadwood has an equity portfolio in which almost a half is represented by healthcare companies, with the largest position being in Questcor Pharmaceuticals Inc (NASDAQ:QCOR) before the company was acquired. Mr. Bradsher also served on Questcor’s board before the company was bought by Mallinckrodt.

Being a micro-cap biopharmaceutical company, BioTime has been advancing in terms of research in different areas through its subsidiaries. Among the latest developments, BioTime, Inc. (NYSEMKT:BTX) filed an Investigational New Drug application with the US FDA to initiate clinical trial of its OpRegen drug for the treatment of the dry form of age-related macular degeneration, which is considered to open a significant market opportunity for the company. In addition, the company and its subsidiaries have recently secured around $31 million in financing for its research and development projects.

Being a long-term investor, with most positions in its equity portfolio being represented by the same companies for several years, Mr. Bradsher managed to secured some significant returns. For example, the aforementioned Questcor Pharmaceuticals Inc (NASDAQ:QCOR) surged by over 1,600% over the last five years before being aquired. Other stakes on which Mr. Bradsher has bet have also provided generally positive returns over the years.

Disclosure: none

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!